sur OXURION (EBR:OXUR)
Oxurion to Acquire Majority Stake in Axiodis CRO
In a significant move, Oxurion NV announced a binding agreement to acquire 72% of Axiodis CRO's share capital. The transaction, valued at €468,000, positions the total company worth at €650,000. Completion is anticipated by June 2025, pending two conditions. Axiodis CRO, established in 2022, operates within clinical biometrics, offering comprehensive data management services in clinical trials through its Exagis software. This acquisition aligns with Oxurion's strategic shift towards integrating advanced clinical data capabilities, expanding their biopharmaceutical influence. Axiodis CRO forecasts increased revenue, aiming for over €2M by 2027, with plans for team expansion and technological development to enhance its market presence. The acquisition funding involves a shareholder loan from Oxurion, illustrating confidence despite financing challenges.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de OXURION